Literature DB >> 33082532

Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world.

Ashish Sharma1, Nilesh Kumar2, Nikulaa Parachuri2, Sonali Singh3, Francesco Bandello4, Baruch D Kuppermann5, Anat Loewenstein6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33082532      PMCID： PMC8182886          DOI： 10.1038/s41433-020-01227-w

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Avastin doesn't blind people, people blind people.

Authors:  Serafin Gonzalez; Philip J Rosenfeld; Michael W Stewart; Jennifer Brown; Steven P Murphy
Journal:  Am J Ophthalmol       Date:  2012-02       Impact factor: 5.258

2.  Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.

Authors:  M C Holland; J U Wurthner; P J Morley; M A Birchler; J Lambert; M Albayaty; A P Serone; R Wilson; Y Chen; R M Forrest; J C Cordy; D A Lipson; A I Bayliffe
Journal:  J Clin Immunol       Date:  2013-07-06       Impact factor: 8.317

3.  Advanced Coats' disease treated with intravitreal brolucizumab combined with laser photocoagulation.

Authors:  Nimesh A Patel; Audina M Berrocal; Timothy G Murray; Victor M Villegas
Journal:  Am J Ophthalmol Case Rep       Date:  2020-07-02

4.  Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.

Authors:  Sara J Haug; Doan Luong Hien; Gunay Uludag; Than Trong Tuong Ngoc; Sherin Lajevardi; M Sohail Halim; Yasir J Sepah; Diana V Do; Arshad M Khanani
Journal:  Am J Ophthalmol Case Rep       Date:  2020-03-31

5.  Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations.

Authors:  Atul Jain; Sophaktra Chea; Wataru Matsumiya; M Sohail Halim; Çigdem Yaşar; Guoping Kuang; Yasir J Sepah; Arshad M Khanani; Diana V Do; Quan Dong Nguyen
Journal:  Am J Ophthalmol Case Rep       Date:  2020-04-02
  5 in total
  7 in total

1.  Idiopathic retinal arterial occlusive vasculitis in the setting of multiple arterial occlusions.

Authors:  Patrick Wang; Eric K Chin; David Rp Almeida
Journal:  Am J Ophthalmol Case Rep       Date:  2021-04-08

Review 2.  Side Effects of Brolucizumab.

Authors:  Tahmineh Motevasseli; Saeed Mohammadi; Fatemeh Abdi; William R Freeman
Journal:  J Ophthalmic Vis Res       Date:  2021-10-25

3.  Bilateral blindness after uneventful brolucizumab injection for macular degeneration.

Authors:  Ilan Barchichat; Michael Thiel; Oliver Job; Martin Schmid
Journal:  BMC Ophthalmol       Date:  2022-02-16       Impact factor: 2.209

4.  Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting.

Authors:  Anne Rübsam; Saskia Rau; Daniel Pilger; Oliver Zeitz; Antonia M Joussen
Journal:  J Ophthalmol       Date:  2022-03-25       Impact factor: 1.909

Review 5.  A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.

Authors:  Frank G Holz; Tomohiro Iida; Ichiro Maruko; SriniVas R Sadda
Journal:  Retina       Date:  2022-06-13       Impact factor: 3.975

6.  Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.

Authors:  Ryo Mukai; Hidetaka Matsumoto; Hideo Akiyama
Journal:  PLoS One       Date:  2021-12-06       Impact factor: 3.240

7.  Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.

Authors:  Sarah Thiele; Frank G Holz; Louisa Maria Bulirsch; Marlene Saßmannshausen; Jennifer Nadal; Raffael Liegl
Journal:  Br J Ophthalmol       Date:  2021-04-12       Impact factor: 5.908
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.